Literature DB >> 21571983

Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations.

S Forsyth1, P Penney, G Rooney.   

Abstract

A 40-year-old man who has sex with men (MSM) with urethral gonorrhoea failed to respond to treatment with 400 mg cefixime orally. Laboratory isolation of the post-treatment strain showed a minimum inhibitory concentration of ≥0.25 mg/L, which is a level of tolerance to cefixime that has not been previously documented in the UK. This case illustrates the importance of assessing all patients after treatment for gonorrhoea so that treatment failure and antibiotic resistance can be identified. It is vital that gonorrhoea culture continues to be attempted from all infected individuals to enable accurate diagnosis and antibiotic sensitivities. We also recommend that laboratories test for cefixime sensitivity routinely, given that it is one of the most commonly prescribed treatments for gonorrhoea.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571983     DOI: 10.1258/ijsa.2009.009191

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  10 in total

Review 1.  The use of cephalosporins for gonorrhea: an update on the rising problem of resistance.

Authors:  Juliet E Stoltey; Pennan M Barry
Journal:  Expert Opin Pharmacother       Date:  2012-05-30       Impact factor: 3.889

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 3.  Expedited partner therapy for sexually transmitted infections.

Authors:  Matthew Hogben; Sarah Kidd; Gale R Burstein
Journal:  Curr Opin Obstet Gynecol       Date:  2012-10       Impact factor: 1.927

4.  Management of Gonorrhea in Adolescents and Adults in the United States.

Authors:  Sarah Kidd; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

5.  Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.

Authors:  Clare Brittain; Margaret Childs; Lelia Duley; Jan Harding; Trish Hepburn; Garry Meakin; Alan A Montgomery; Wei Tan; Jonathan D C Ross
Journal:  Trials       Date:  2016-11-24       Impact factor: 2.279

6.  Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study.

Authors:  Lilith K Whittles; Peter J White; Xavier Didelot
Journal:  PLoS Med       Date:  2017-10-31       Impact factor: 11.069

7.  Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility.

Authors:  Xiaomeng Deng; Lao-Tzu Allan-Blitz; Jeffrey D Klausner
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

8.  Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012-2016.

Authors:  I Martin; P Sawatzky; V Allen; B Lefebvre; Lmn Hoang; P Naidu; J Minion; P Van Caeseele; D Haldane; R R Gad; G Zahariadis; A Corriveau; G German; K Tomas; M R Mulvey
Journal:  Can Commun Dis Rep       Date:  2019-02-07

9.  Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.

Authors:  Michelle J Cole; Gianfranco Spiteri; Susanne Jacobsson; Rachel Pitt; Vlad Grigorjev; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2015-08-11       Impact factor: 3.090

Review 10.  Epidemiological Trends of Antibiotic Resistant Gonorrhoea in the United Kingdom.

Authors:  Lilith K Whittles; Peter J White; John Paul; Xavier Didelot
Journal:  Antibiotics (Basel)       Date:  2018-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.